Glaucoma is a common optic neuropathy that can lead to irreversible vision loss, and intraocular pressure (IOP) is the only known modifiable risk factor. The primary method of treating glaucoma involves lowering IOP using medications, laser and/or invasive surgery. Currently, we rely on in-office measurements of IOP to assess diurnal variation and to define successful management of disease. These measurements only convey a fraction of a patient's circadian IOP pattern and may frequently miss peak IOP levels. There is an unmet need for a reliable and accurate device for 24-h IOP monitoring. The 24-h IOP monitoring devices that are currently available and in development fall into three main categories:
INTRODUCTION
Glaucoma is a leading cause of irreversible blindness with a global impact that is estimated to include 60.5 million patients [1, 2] . To date, intraocular pressure (IOP) is the only modifiable risk factor. Treatment decisions are based on in-office measurements of IOP to assess diurnal variation and to define successful management of disease; however, these These patients were known to have confirmed progression based on perimetry despite ''well-controlled'' IOP measurements during clinic visits. Their 24-h IOP curve was compared to their previously measured clinic-based IOP curve while maintaining their current glaucoma medication regimen. The mean IOP value was similar between the two groups; however, the peak 24-h IOP was 4.9 mmHg higher than the clinic-based diurnal curve (p\0.0001). In addition, the 24-h IOP curve for four patients demonstrated at least a 12 mmHg increase in peak IOP. Approximately 51.7% of patients recorded their peak IOP outside standard office hours, although no specific aggregate pattern was revealed [5] .
Similarly, another retrospective study reviewed the 24-h IOP curve obtained in a hospital sleep laboratory for 32 patients with POAG with known progression. The 24-h IOP curve demonstrated a wider range (6.9 ± 2.9 vs.
3.8 ± 2.3 mmHg; p\0.001) and a higher peak IOP for 62% of patients when compared to office-based measurements [6] . [7] .
At present, hospitalization in a sleep laboratory for serial measurements is required to obtain a patient's 24-h IOP curve, which is both cumbersome and expensive [8] . In addition, the gold standard for measuring IOP, Goldmann applanation tonometry (GAT), can be influenced by multiple variables that include pachymetry, keratometry, the amount of fluorescein in the tear film, Valsalva, eye position, and interobserver error [9, 10] .
In the era of advanced bioinformatics, there is a need for a more accurate and precise method of continuous IOP monitoring, which will allow physicians to better understand the nature of their patient's disease process and thus improve treatment regimens. Devices that are currently available and in development fall into three main categories: patient self-monitoring, temporary continuous monitoring, and permanent continuous monitoring (Table 1) .
This article is a systematic review of current devices for 24-h IOP monitoring that follows the principles of the Rapid Evidence Assessment methodology. It is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
SELF-MONITORING DEVICES
Many handheld, portable self-monitoring devices have been proposed and evaluated on the basis of ease of use, portability, safety profile, reliability, and accuracy.
The Tono-Pen (Reichert Technologies, Depew, NY, USA) [11] is a portable device that relies on the principles of applanation tonometry to measure IOP. It is reputable for its strong correlation with Goldmann applanation at physiologic pressures [12, 13] and is widely used in a variety of clinical settings. However, it has not been advocated for home self-monitoring because it requires the use of a topical anesthetic, which is associated with corneal endothelial toxicity [14, 15] .
In 1998, it was suggested that IOP has a direct correlation to the amount of external pressure that needs to be applied to the ocular surface to create a visual aura, or phosphene.
On the basis of these observations, the Proview Eye Pressure Monitor (Bausch and Lomb, Rochester, NY, USA) was introduced. The device has a circular tip that is applied to the eyelid at the superonasal quadrant, and the patient applies increasing external pressure until a visual aura is produced and the corresponding IOP is then recorded. The device is portable, does not require a topical anesthetic, and is easy and safe to use.
However, clinical studies have shown a poor correlation with GAT and Tono-Pen measurements [14, [16] [17] [18] .
Dekking and Coster first described the principle of rebound tonometry (RT) in 1967 [19, 20] . This discovery led to the development of the iCare tonometer (iCare Finland) [21] , which was introduced in the USA in 2007. It is a handheld device that consists of a metallic motion probe with a plastic tip that is poised in a coil system. The probe accelerates towards of the remaining four measurements [22] . No topical anesthetic is required and the iCare tonometer has demonstrated a strong correlation with Goldmann applanation [22] [23] [24] . However, it has been noted that corneal properties, which include central corneal thickness (CCT), corneal hysteresis (CH), and corneal resistance factor (CRF), can affect the accuracy of IOP measurements [25, 26] . The iCare tends to overestimate IOP when compared to GAT in patients with thicker CCT [22] [23] [24] but is more reliable at the peripheral cornea [27, 28] and is independent of corneal curvature [29] .
In addition, the reliability and accuracy decline when there is misalignment, which can be influenced by head position, dexterity, and eye movement. The traditional iCare model may be used in the upright or lateral decubitus position but is unable to measure supine IOP because of probe displacement when the device is inverted [14, 16, 22, 30] . The new iCare Pro has a built-in inclination sensor that allows IOP measurements in the supine position [31] . The US model and iCare Pro require the participation of a separate observer but can be easily used by non-specialized personnel with minimal training.
There are two iCare models designed for self-monitoring that are currently available outside the USA, namely the iCare Home ( Fig. 1 ) and its predecessor, the iCare One.
Clinical trials have demonstrated that self-monitoring IOP measurements taken by iCare One have a strong correlation to GAT measurements with patients reporting subjective ease of use [32] [33] [34] . The current updates to the iCare design increase its potential for widespread use as a portable IOP self-monitoring device.
In one study, the concurrent measurements using the self-monitoring iCare One and clinician-obtained GAT IOP were compared for 149 patients with ocular hypertension (OHT) and glaucoma. The iCare One IOP values were within 3 mmHg of corresponding GAT values for 67.1% of patients. The differences noted between the iCare One and GAT were not significant (p = 0.41) if the dominant hand was used for self-monitoring. In addition, more than 77% of participants reported ease of use with the iCare One [34] .
A recent study investigated the accuracy of self-obtained, partner-obtained, and trainerobtained iCare Home IOP measurements compared to GAT. After a standardized training regimen, 74% of subjects were able to successfully use the iCare Home for selfmonitoring. The acceptability questionnaire revealed that the device was easy to use (84%), measurements were quick to obtain (88%), and the device was comfortable (95%). However the iCare Home was inclined to underestimate the IOP compared to GAT: self-obtained IOP, 0.3 mmHg (95% CI -4.6 to 5.2 mmHg); demonstrated the least discrepancy with GAT, although there was a greater difference noted for CCT below 500 mm and above 600 mm [35] .
TEMPORARY CONTINUOUS MONITORING DEVICES
In the 1970s, Greene and Gilman proposed the use of contact lenses for continuous IOP monitoring. They embedded two strain gauges in a soft contact lens and measured the changes in the meridional angle of the cornea-scleral junction to assess fluctuations in IOP [36] . Given the necessity to custom fit each contact lens, cost became an insurmountable barrier to its widespread use [37] .
The next attempt followed a few decades later. Ziemer Ophthalmic Systems introduced a rigid gas-permeable contact lens (RGP) with a piezoresistive pressure sensor that was centered within the lens and seated flush to the posterior surface. [37, 42] . To date, the Triggerfish CLS has been used to study the circadian pattern in healthy individuals, as well as those with POAG, NTG, PXG [44, 45] and patients with thyroid eye disease [46] .
Use of the CLS has provided new insights into the effects of selective laser trabeculoplasty (SLT). In a prospective study, 18 NTG patients underwent SLT. Their baseline and 1-month 24-h IOP curves were obtained with the Triggerfish CLS for comparison. Patients with successful treatment, as defined by an IOP reduction of at least 20% by GAT, displayed a 24.6% reduction of mean global variability at 1 month. There was no change in signal variability noted in the success group, whereas the patients that failed treatment demonstrated an increase in diurnal variability [47] . A similar study compared the baseline, 1-month, and 2-month CLS 24-h IOP curves for 10 patients with NTG who underwent SLT. In patients that were successfully treated, the range of IOP fluctuations during the diurnal period remained unchanged while the fluctuations during the nocturnal period decreased from 290 ± 86 mV Eq to 199 ± 31 mV Eq after treatment (p = 0.014) [48] .
In regards to topical medications, the Triggerfish CLS has struggled to demonstrate were immersed in saline for 515 days and were subjected to an absolute test pressure of 1000 hPa (sea level) at 36°C. The average drift in intraocular pressure was 3.47 mmHg compared to the calculated drift rate of 2.46 mmHg, confirming that the measurements taken maintained a practical precision when tested under simulated physiologic conditions [55] . In vitro studies have demonstrated that the Implandata EyeMate is biocompatible with good subjective tolerance in rabbit eyes for up to 25 months. This was confirmed by the lack of intraocular toxicity on histopathology [55, 56] .
In the ARGOS-O1 study, six patients with well-controlled POAG or NTG and visually significant cataracts underwent an uneventful cataract surgery and sulcus placement of the Implandata EyeMate (Fig. 3) , which was confirmed by ultrasound biomicroscopy. Four patients demonstrated a significant postoperative inflammatory response that lasted up to 9 days and was successfully treated with topical and oral steroids. At 1 year postoperatively, all patients maintained control of their glaucoma and there was no incidence of pupillary block, angle closure, corneal edema, retinal detachment, endophthalmitis, bleeding, macular edema, or visual deterioration. The endothelial cell count and central corneal thickness remained stable in all patients [57] .
Although the telemetric intraocular pressure curves for all patients were comparable to the circadian pattern outlined by consecutive IOP measurements by GAT, three patients had a significant positive shift in their telemetric IOP curves after 5-6 months and one patient consistently had a negative telemetric IOP curve despite stable GAT readings. The sensor's unpredictable variance leads to issues concerning the interpretation and clinical application of the WIT telemetric curves.
Consecutive GAT measurements are likely to be necessary as a benchmark for comparison until we are able to formulate guidelines for interpretation based on additional evidence-based research [57] .
Currently, there is an open enrollment for a prospective, multicenter clinical trial to assess the safety and efficacy of the device for patients 
